Analysts Anticipate Chimerix Inc (CMRX) to Post -$0.43 Earnings Per Share

Equities research analysts expect Chimerix Inc (NASDAQ:CMRX) to report earnings of ($0.43) per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Chimerix’s earnings, with estimates ranging from ($0.45) to ($0.40). Chimerix posted earnings per share of ($0.38) during the same quarter last year, which would suggest a negative year-over-year growth rate of 13.2%. The business is expected to announce its next quarterly earnings results on Tuesday, May 8th.

According to Zacks, analysts expect that Chimerix will report full-year earnings of ($1.79) per share for the current financial year, with EPS estimates ranging from ($1.87) to ($1.64). For the next year, analysts expect that the business will report earnings of ($1.73) per share, with EPS estimates ranging from ($1.97) to ($1.20). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Chimerix.

How to Become a New Pot Stock Millionaire

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.07. Chimerix had a negative net margin of 1,579.53% and a negative return on equity of 29.22%. The business had revenue of $1.84 million during the quarter, compared to the consensus estimate of $0.83 million.

A number of analysts recently issued reports on the stock. JPMorgan Chase & Co. downgraded shares of Chimerix from a “neutral” rating to an “underweight” rating in a report on Wednesday, February 14th. HC Wainwright assumed coverage on shares of Chimerix in a research note on Friday, February 2nd. They issued a “buy” rating and a $10.00 target price for the company. BidaskClub upgraded shares of Chimerix from a “hold” rating to a “buy” rating in a research note on Friday, March 9th. Zacks Investment Research upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Finally, Cowen reiterated a “hold” rating and issued a $6.00 target price on shares of Chimerix in a research note on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $7.06.

Chimerix stock traded down $0.17 during midday trading on Friday, reaching $5.32. 145,664 shares of the company were exchanged, compared to its average volume of 174,981. Chimerix has a 1-year low of $4.17 and a 1-year high of $6.60. The stock has a market capitalization of $253.51, a P/E ratio of -3.50 and a beta of 1.34.

Institutional investors and hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new position in shares of Chimerix in the fourth quarter worth about $137,000. The Manufacturers Life Insurance Company increased its stake in shares of Chimerix by 8.3% in the second quarter. The Manufacturers Life Insurance Company now owns 39,628 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 3,042 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Chimerix in the fourth quarter worth about $280,000. Nationwide Fund Advisors increased its stake in shares of Chimerix by 70.3% in the third quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 24,994 shares in the last quarter. Finally, Millennium Management LLC increased its stake in shares of Chimerix by 54.3% in the fourth quarter. Millennium Management LLC now owns 77,024 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 27,096 shares in the last quarter. Hedge funds and other institutional investors own 74.33% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Analysts Anticipate Chimerix Inc (CMRX) to Post -$0.43 Earnings Per Share” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3300008/analysts-anticipate-chimerix-inc-cmrx-to-post-0-43-earnings-per-share.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

First Internet Bancorp’s  Buy Rating Reiterated at Maxim Group
First Internet Bancorp’s Buy Rating Reiterated at Maxim Group
Show  Reaches Market Cap of $0.00
Show Reaches Market Cap of $0.00
PayCoin  Price Tops $0.0344 on Major Exchanges
PayCoin Price Tops $0.0344 on Major Exchanges
UGAIN Price Reaches $0.0031
UGAIN Price Reaches $0.0031
Reviewing Sally Beauty  and Kirkland’s Home
Reviewing Sally Beauty and Kirkland’s Home
Comparing CGG  and Paramount Resources
Comparing CGG and Paramount Resources


© 2006-2018 Ticker Report. Google+.